Green Cross

R&D INNOVATION

R&D pipeline

11

+
Class 2 innovative drugs

2

+
Class 1 innovative drugs

12

+
Varieties Under Review

13

+
Innovative Drugs Developed In-House

R&D team
Professor-Level Senior Engineer
Hu Gongyun

A graduate of East China University of Science and Technology, he has over 40 years of experience in the pharmaceutical industry; he is a licensed pharmacist and a postdoctoral advisor; he serves as Vice President of Guangzhou Green Cross Pharmaceutical Group; and concurrently serves as Director of the Liposomal Drug Formulation Technology Platform at Green Cross Group.

Senior Engineer
Wang Duantong

Over 30 years of experience in the pharmaceutical industry; General Manager of Guangdong Saifeng Pharmaceutical Technology Co., Ltd.; Licensed Pharmacist; and Deputy Director of the Liposomal Drug Formulation Technology Platform at Green Cross Group.

Chief Scientist
Cheng Xiuxiu

With nearly 30 years of experience in pharmaceutical formulation and product development, he has been granted more than 30 U.S. patents; he holds a bachelor’s and master’s degree from East China University of Science and Technology and is a Chinese-American.

Senior Technical Director of Raw Material R&D
Chen Rongmin

With nearly 30 years of experience in pharmaceutical formulation and product R&D, he has been granted more than 30 U.S. patents; he holds a Bachelor’s degree in Chemistry from Peking University and a Master’s degree from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; he holds three authorized invention patents in China and 10 published invention patents.

Director of Formulation R&D
Guo Liangran

Ph.D. from Fudan University; Postdoctoral Fellow at the University of Rhode Island; Conducted postdoctoral research at the University of Rhode Island from 2011 to 2015; Has spent many years engaged in the research and development of novel drug delivery systems and formulations, including injectables, complex injectables, and oral solid dosage forms

Senior Technical Director of Formulation Development; Manager of the R&D Department
Bu Shui

Guangdong Pharmaceutical University, Master’s Degree; Licensed Pharmacist with 15 years of experience in pharmaceutical formulation research and development; led the development of multiple oral solid dosage forms and injectable formulations that were approved for market release, covering various therapeutic areas; during this period, was granted two invention patents and filed two international PCT patent applications.

Patent Display

A Lansoprazole Tablet Composition and Method for Its Preparation

2025.07.04

An Easy-to-Clean, High-Efficiency Dust Collection Cartridge for a Fluidized Bed Dryer

2025.06.24

A pusher mechanism for a cartoning machine suitable for various plate heights

2025.06.20

A Method for the Detection of Trace Amounts of L-Proline in L-Proline

2025.03.11

A tableting apparatus for the production of solid dosage forms

2024.11.29

A Metal Detector for the Production of Solid Dosage Forms

2024.10.01

A Vacuum Sterilization Device for Ampoules

2024.09.10

A Leak Detection Device for Flexible Bags

2024.07.02

1 2 3 4 5 6 7

R&D laboratory
Amino acids
Amino Acid Formulation Technology Platform
We have already established a range of amino acid products and are continuously improving quality and driving technological innovation based on our existing product portfolio. By leveraging our Key Laboratory of Amino Acids, we are building a technology p
View Details
Slow-release drugs
Sustained- and Controlled-Release Drug Delivery Technology Platform
The sustained- and controlled-release formulations developed using the company’s sustained- and controlled-release technology platform encompass a variety of types, including osmotic pump-controlled release, matrix-controlled release, and delayed-release
View Details
Lipid microspheres
Liposomal Drug Delivery Technology Platform
Building on its in-house research and development of the original formulation of dexamethasone palmitate injection (Dolisun), the company has established a liposome-based drug delivery technology platform. It is committed to leveraging this platform to ex
View Details

R&D investment
2019
31,548,500 yuan
R&D Expense Ratio: 11.52%
2020
50,861,500 yuan
R&D Expense Ratio: 9.28%
2021
78,875,400 yuan
R&D Expense Ratio: 10.00%
2022
85,833,000 yuan
R&D Expense Ratio: 11.72%
2023
100,003,100 yuan
R&D Expense Ratio: 13.51%
2024
809,050,000 yuan
R&D Expense Ratio: 11.90%